MyBlueDotsAlentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis MyBlueDots2 weeks ago01 mins BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile Post navigation Previous: Henry Schein Opens Customer Emergency Support Hotline in Response to California FiresNext: What Illinois residents should know, following the first US death from bird virus
People who are autistic and transgender/gender diverse have poorer health and health care, study finds MyBlueDots17 hours ago 0
Digital therapeutics: Exploring the road to commercialization across international markets MyBlueDots21 hours ago 0